Effects of troglitazone on insulin sensitivity.

Studies to date confirm that troglitazone has therapeutic benefits to NIDDM and can normalize IGT in those individuals at increased risk of developing NIDDM. Hyperinsulinaemia is reduced by such treatment in association with reduced insulin resistance and there are favourable effects on blood pressure with troglitazone therapy as well. Since insulin resistance and hyperinsulinaemia are usually present in obesity and impaired glucose tolerance (IGT), troglitazone may be useful in preventing the development of NIDDM in these susceptible populations.